Navigation Links
Seventh Sense Biosystems Receives CE Mark Approval for its Touch Activated Phlebotomy Blood Collection and Testing System
Date:11/4/2013

CAMBRIDGE, Mass., Nov. 4, 2013 /PRNewswire/ -- Seventh Sense Biosystems, Inc., the leading developer of painless blood collection and diagnostic platforms, today announced it has obtained CE Mark approval for its Touch Activated Phlebotomy (TAP™) platform for blood collection and testing.

"This first regulatory approval is a significant milestone in our goal of expanding the reach of blood-based point-of-care diagnostics to a majority of patients, regardless of geography or setting," said Howard Weisman, CEO and President of Seventh Sense. "When fully commercialized, the TAP platform will incorporate additional capabilities for sample separation as well as dried blood spot and on-board diagnostic capabilities."

Studies show that a positive patient experience is closely linked to compliance with a prescribed treatment. Seventh Sense will be developing and commercializing novel diagnostic tools that are specially engineered to eliminate the pain and anxiety that can prevent patients from receiving appropriate care. The company's proprietary innovations in microneedle and microfluidic technology enable the collection of a stable, secure and high quality blood sample without painful lancing or the need for highly skilled medical personnel.

"We've surveyed patients and their physicians around the world and found a significant need for near painless, simple-to-use, and reliable blood collection and diagnostic devices that has so far been unmet," said Weisman.

The company plans to scale-up manufacturing capability in 2014 and continue the development of follow-on products for patients and clinicians in the Americas, Europe and Asia-Pacific regions.

About the Touch Activated Phlebotomy Device
Touch Activated Phlebotomy (TAP™) is a proprietary platform that draws capillary blood in a painless, one-step process without having to access a vein and it can be utilized across and integrated with a broad spectrum of diagnostic applications. The TAP system penetrates the uppermost layers of skin through the use of micro-needles, collects capillary blood using a novel microfluidic extraction process, and stabilizes the blood with anticoagulant if required. The device has a visual indicator to confirm that collection is complete. The TAP platform is designed for fully automated, high throughput manufacturing.

About Seventh Sense Biosystems, Inc.
Founded in 2008, within Flagship VentureLabs™, Seventh Sense is developing an array of products based on the company's proprietary Touch Activated Phlebotomy (TAP™) painless blood collection platform, with an initial focus on enabling important diagnostic testing at the point of care by reducing the discomfort, anxiety and hassle of blood sample collection.  Seventh Sense is backed by leading investors Flagship Ventures and Polaris Partners.  For more information, please visit www.7sbio.com.

For media inquiries contact:
Tim Richards
617-547-7246  ext. 222
info@7sbio.com

 


'/>"/>
SOURCE Seventh Sense Biosystems, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Hyland Software Hosts Seventh Annual OnBase/Epic User Forum
2. AUL Files Seventh Brief Supporting First Amendment Freedom of Conscience
3. Volcano Corporation Announces Webcast Of March Seventh Analyst Day
4. 3-V Biosciences To Present at the Seventh Annual JMP Securities Healthcare Conference
5. Arena Pharmaceuticals to Present at the Seventh Annual JMP Securities Healthcare Conference
6. Israeli Medical Device Company FlowSense Acquired by Baxter
7. iSonea Receives Frost & Sullivan New Product Innovation Leadership Award for its Path-Breaking Mobile Asthma Monitoring App, AsthmaSense
8. AuraSense Therapeutics Closes Tranche II of Series B Equity Investment
9. Deceptive Practices By Illegal Online Drug Sellers Give Consumers a False Sense of Legitimacy and Safety, Reports NABP
10. Xenon Licenses Antisense Drug XEN701 From Isis and Initiates Preclinical Toxicology Studies
11. Clinical Team Researching the Impact of the EarlySense System Wins Best Novel Idea Prize at the Rapid Response Systems and Medical Emergency Teams 2013 8th International Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2017)... The Rebound mobile app is poised to become a vital ... prescription drug addiction. The app empowers users to develop an ... their dosage in a safe, controlled manner while maximizing well-being. ... 100,000 people to sign up will enjoy 3 months of ... ...
(Date:9/25/2017)... , Sept. 25, 2017   Montrium ... Master File solutions, today—from the IQPC Trial Master ... , NL)—announced that EastHORN Clinical Services has ... clinical programs and TMF management. EastHORN, a leading ... eTMF platform to increase transparency to enable greater ...
(Date:9/19/2017)... 2017 HistoSonics, Inc., a venture-backed medical device company developing a non-invasive, robotically assisted, ... three leadership team developments today:   ... ... Tom Tefft ... Veteran medical device executive Josh Stopek , PhD, who has ...
Breaking Medicine Technology:
(Date:10/12/2017)... ... October 12, 2017 , ... IsoComforter, Inc. ( https://isocomforter.com ), one ... an innovative new design of the shoulder pad. The shoulder pad provides optimal ... controlling your pain while using cold therapy. By utilizing ice and water that is ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... AccentCare, a leader in post-acute health care, have expanded their existing home health ... Home Health. , AccentCare has been operating a joint venture home health company ...
(Date:10/12/2017)... ... October 12, 2017 , ... Dr. Parsa Mohebi, the ... medical article to the newly revamped Cosmetic Town journal section, featuring ... transplant procedure known as Follicular Unit Extraction (FUE). , Dr. Mohebi ...
(Date:10/12/2017)... ... ... Leading pediatric oncology experts at Children’s National Health System will ... the International Society of Paediatric Oncology (SIOP) Oct. 12-15. Chaired by Jeffrey ... Disorders at Children’s National, and Stephen P. Hunger, M.D., Chief of the Division ...
(Date:10/12/2017)... ... October 12, 2017 , ... Women-owned and Grand ... Best and Brightest in Wellness® by Best and Brightest. OnSite Wellness will be ... Oct. 20 from 7:30 a.m. to 2 p.m. at the Henry Autograph Collection ...
Breaking Medicine News(10 mins):